((自动化翻译由路透提供，请见免责声明 ))
10月24日 - ** 疗法开发商Marinus Pharmaceuticals 的股价盘前下跌~61.5%至65美分
** 该公司称，在一项针对罕见遗传性脑部疾病 "结节性硬化综合征"（tuberous sclerosis complex(TSC）患者的后期试验中，其口服药物甘纳昔隆（ganaxolone）未能达到主要目标，因此该公司将停止 (link)。)
** MRNS 公司称，该药物并未显著降低 TSC 相关性癫痫发作的频率。
** 该公司称正在探索战略替代方案，并采取更多措施降低成本，包括裁员
** 截至上次收盘，股价年累计下跌 84.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.